Key Details
Annual ROE
-156.20%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 07, 2024Recent annual earnings:
Sept 23, 2020Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with ENOB included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Enochian Biosciences doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Enochian Biosciences?
- What is the ticker symbol for Enochian Biosciences?
- Does Enochian Biosciences pay dividends?
- What sector is Enochian Biosciences in?
- What industry is Enochian Biosciences in?
- What country is Enochian Biosciences based in?
- When did Enochian Biosciences go public?
- Is Enochian Biosciences in the S&P 500?
- Is Enochian Biosciences in the NASDAQ 100?
- Is Enochian Biosciences in the Dow Jones?
- When was Enochian Biosciences's last earnings report?
- When does Enochian Biosciences report earnings?
What is the primary business of Enochian Biosciences?
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
What is the ticker symbol for Enochian Biosciences?
The ticker symbol for Enochian Biosciences is NASDAQ:ENOB
Does Enochian Biosciences pay dividends?
No, Enochian Biosciences does not pay dividends
What sector is Enochian Biosciences in?
Enochian Biosciences is in the Healthcare sector
What industry is Enochian Biosciences in?
Enochian Biosciences is in the Biotechnology industry
What country is Enochian Biosciences based in?
Enochian Biosciences is headquartered in United States
When did Enochian Biosciences go public?
Enochian Biosciences's initial public offering (IPO) was on 07 February 2018
Is Enochian Biosciences in the S&P 500?
No, Enochian Biosciences is not included in the S&P 500 index
Is Enochian Biosciences in the NASDAQ 100?
No, Enochian Biosciences is not included in the NASDAQ 100 index
Is Enochian Biosciences in the Dow Jones?
No, Enochian Biosciences is not included in the Dow Jones index
When was Enochian Biosciences's last earnings report?
Enochian Biosciences's most recent earnings report was on 7 March 2024
When does Enochian Biosciences report earnings?
The date for Enochian Biosciences's next earnings report has not been announced yet